SciELO - Scientific Electronic Library Online

 
vol.14 número1Stress oxidativo na lesão pulmonar neonatalOs abcessos pulmonares em revisão índice de autoresíndice de assuntosPesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista Portuguesa de Pneumologia

versão impressa ISSN 0873-2159

Rev Port Pneumol v.14 n.1 Lisboa fev. 2008

 

Sarcoidose extratorácica

Extra-thoracic sarcoidosis

 

Filipa Costa 1

Ana Arrobas 2

 

Resumo

A sarcoidose é uma doença granulomatosa multissistémica de etiologia desconhecida, caracterizada histologicamente pela presença de granulomas não caseosos nos órgãos envolvidos. Trata-se de uma doença que pode envolver praticamente qualquer órgão, manifestando-se de múltiplas formas e apresentando-se a várias especialidades clínicas. O envolvimento extratorácico isolado é raro (10%), surgindo mais frequentemente associado ao envolvimento pulmonar ou dos gânglios linfáticos mediastínicos.

A nível extratorácico pode ocorrer, entre outros, envolvimento do fígado (50-80%), baço (40-80%), olho (20-50%), nódulos linfáticos periféricos (30%), pele (25%), sistema nervoso (10%), coração (5%), rim e aparelho músculo-esquelético, nem sempre cursando com sintomatologia. A presença de envolvimento extratorácico afecta muitas vezes o prognóstico e a atitude terapêutica da sarcoidose.

Os autores fazem uma revisão das principais manifestações extratorácicas da sarcoidose, abordando as suas manifestações clínicas, diagnóstico, tratamento, seguimento e prognóstico.

Palavras-chave: Sarcoidose, extratorácica.

 

 

Abstract

Sarcoidosis is a multisystemic granulomatous disease of unknown aetiology, characterized by the presence of non-caseating epithelioid cell granulomas on tissue biopsy of affected organs. It may involve any organ, presenting in multiple forms to clinicians of different specialities.

In its extra-thoracic form it may involve the liver (50-80%), spleen (40-80%), eye (20-50%), extrathoracic lymph nodes (30%), skin (25%), nervous system (10%), heart (5%), kidney, muscle and bone, sometimes without symptoms. The presence of extrathoracic disease may affect the prognosis and treatment options for sarcoidosis.

The authors present a review of the major extra-thoracic manifestations of sarcoidosis regarding its clinical presentation, diagnosis, treatment, follow-up and prognosis.

Key-words: Sarcoidosis, extra-thoracic.

 

Texto completo disponível apenas em PDF.

Full text only available in PDF format.

 

 

Bibliografia

 

1. Costabel U. Sarcoidosis: clinical update. Eur Respir J 2001; 18(Suppl 32):56s-68s.        [ Links ]

2. Costabel U, Hunninghake GW. ATS/ERS/WASOG statement on sarcoidosis. Eur Respir J 1999; 14:735-7.

3. Moller RD. Rare manifestations of sarcoidosis. Eur Respir Mon 2005; 32:233-50.

4. James DG, Sherlock S. Sacoidosis of the liver. Sarcoidosis 1994; 11:2-6.

5. Vatti R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:73-6.

6. Israel HL, Goldstein LA. Hepatic granulomatosis and sarcoidosis. Ann Intern Med 1973; 79:669-78.

7. Martín Santos JM. Sarcoidosis. Medicine 2001; 8(33):1715-22.

8. Padilla ML, Schilero GJ, Teirstein AS. Sarcoidosis and transplantation. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:16-22.

9. Segorbe Luis A. Sarcoidose. In Marques Gomes MJ, Sotto-Mayor R (Eds.). Tratado de Pneumologia da Sociedade Portuguesa de Pneumologia. Lisboa: Permanyer, 2003: 1327-38.

10. Katarina YP, Whitcomb ME. Splenomegaly in sarcoidosis. Arch Intern Med 1980; 140:35-7.

11. Eklund A, Grunewald J. Sarcoidosis. In Gibson GJ, Geddes DM, Costabel U, Sterk PJ, Corrin B (Eds.). Respiratory Medicine, 3rd Edition. London: Saunders, 2003: 1603-20.

12. Ohara K., Judson MA, Baughman RP. Clinical aspects of ocular sarcoidosis. Eur Respir Mon 2005; 32:188-209.

13. Mayers M. Ocular sarcoidosis. Int Ophtalmol Clin 1990; 30:257-63.

14. Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophtalmol 1986; 102:297-300.

15. Judson MA, Baughman RP. Sarcoidosis. In: Baughman RP, du Bois RM (Eds.). Diffuse Lung Disease A practical approach. London: Arnold; 2004:109-29.

16. Warshauder DM, Dumbleton SA, Molina PL, et al. Abdominal CT findings in sarcoidosis: radiological and clinical correlation. Radiology 1994; 192:93-8.

17. Eklund A, Rizzato G. Skin manifestations in sarcoidosis. Eur Respir Mon 2005; 32:150-63.

18. Mana J, Marcoval J, Graells J, et al. Cutaneous involvement in sarcoidosis. Arch Dermatol 1997; 133:882-8.

19. Russo G, Millikan LE. Cutaneous sarcoidosis: diagnosis and treatment. Comp Ther 1994; 20:418-21.

20. Volden G. Successful treatment of chronic skin diseases with clobetasol propio nate and a hydrocolloid occlusive dressing. Acta Derm Venereol 1992; 72:69-71.

21. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336:1224-34.

22. Zic JA, Horowitz DH, Arzubiaga C, et al. Treatment of cutaneous sarcoidosis with chloroquine. Arch Dermatol 1991; 127:1034-40.

23. Jones E, Callen JF. Hydroxychloroquine is effective therapy for control of cutaneous sacoidal granulomas. J Acad Dermatol 1990; 23:487-9.

24. Webster GF, Razki LK, Sanchez M, et al. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991; 24:451-4.

25. Pollock JL. Sarcoidosis responding to allopurinol. Arch Dermatol 1980; 116:273-4.

26. Carlesimo M, Guistini S, Rossi A, et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995; 32:866-9.

27. Hoitsma E, Sharma OP. Neurosarcoidosis. Eur Respir Mon 2005; 32:164-87.

28. Sharma OP. Cardiac and neurologic dysfunction in sarcoidosis. Clin Chest Med 1997; 18:813-25.

29. Stern BJ, Krumholz A, Johns C, et al. Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42:909-17.

30. Agbogu BN, Stern BJ, Sewell C, et al. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995; 52:875-9.

31. Schulte W, Kirsten D, Drent M, Costabel U. Cardiac involvement in sarcoidosis. Eur Respir Mon 2005; 32:130-49.

32. Sekiguchi M, Yazaki Y, Isobe M, et al. Cardiac sarcoidosis: diagnostic, prognostic and thera peutic considerations. Cardiovasc Drugs Ther 1996; 10:495-510.

33. Baughman RP, Lower EE. Steroid sparing alternative treatments for sarcoidosis. Clin Chest Med 1997; 18:853-64.

34. Shammas RL, Movahed A. Sarcoidosis of the heart. Clin Cardiol 1993; 16:462-72.

35. Chin BB, Civelek AC, Mudun A. Resting T-201 scintigraphy in the evaluation of myocardial sarcoidosis. Clin Nucl Med 1997; 22:475-8.

36. Winterbauer RH, Kirtland SH, Corley DE. Treatment with corticosteroids. Clin Chest Med 1997; 18:843-851.

37. Sharma OP. Renal sarcoidosis and hypercalcaemia.Eur Respir Mon 2005; 32:220-32.

38. Sharma OP. Vitamin D, calcium and sarcoidosis. Chest, 1996; 109:535-9.

39. Costabel U, Teschler H. Biochemical changes in sarcoidosis. Clin Chest Med 1997; 18:827-42.

40. Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-hydroxyvitamin D and calcium concentration in sarcoidosis associated hypercalcaemia with short-course chloroquine therapy. Ann Intern Med 1989; 111:437-8.

41. Bia MJ, Insogna K. Treatment of sarcoidosis associated hypercalcaemia with ketoconazole. Am J Kidney Dis 1991; 18:702-5.

42. Jansen TLTA, Geusens PPMM. Sarcoidosis: joint, muscle and bone involvement. Eur Respir Mon 2005; 32:210-19.

43. Petterson T. Rheumatic features of sarcoidosis. Curr Opin Rheumatol 1998; 10:73-8.

44. Gran TJ, Bohmer E. Acute sarcoid arthritis: a favourable outcome? Scan J Rheumatol 1996; 25:70-3.

45. Neville E, Walker AN, James DG. Prognostic factors, predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 208:525-33.

46. Kaye O, Palazzo E, Grossin M, et al. Low-dose methotrexate: an effective corticosteroid-sparing agent in musculoskeletal manifestations of sarcoidosis. Br J Rheumatol 1995; 34:642-4.

47. Judson MA, Baughman RP, Terstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:75-86.

48. Kennedy D, Yamakido M. Haematologic manifestations of sarcoidosis. Semin Respir Med 1992; 13:455-8.

49. Browne PM, Sharma OP, Salkin D. Bone marrow sarcoidosis. JAMA 1978; 240:2654-5.

50. Bower JS, Belen JE, Weg JG, et al. Manifestations and treatment of laryngeal sarcoidosis. Am Rev Respir Dis 1980; 122:325-32.

51. Krespi YP, Kuriloff DB, Aner M. Sarcoidosis of the sinonasal tract: a new staging system. Otolaryngol Head Neck Surg 1995; 112:221-7.

52. Shah UK, White JA, Gooey JE, et al. Otolaryngologic manifestations of sarcoidosis: presentation and diagnosis. Laryngoscope 1997; 107:67-75.

53. Scheffield EA. Pathology of sarcoidosis. Clin Chest Med 1997; 18:741-54.

 

 

1 Interna do Internato Complementar de Pneumologia

2 Assistente Hospitalar Graduada de Pneumologia

Serviço de Pneumologia,

Centro Hospitalar de Coimbra

(Director: Dr. Jorge Pires)

Quinta dos Vales

São Martinho do Bispo

3046-853 Coimbra

 

Recebido para publicação/received for publication: 07.02.23

Aceite para publicação/accepted for publication: 07.07.20